Region:

Text Size

  • Smaller
  • Regular
  • Large

Managing MPS VI with NAGLAZYME® (galsulfase)

NAGLAZYME is the first and only enzyme replacement therapy (ERT) for MPS VI. NAGLAZYME is indicated for patients with mucopolysaccharidosis VI (MPS VI).

Integrative care – the role of palliative and targeted therapy

For decades, the only treatment available for most MPS VI patients was supportive, symptom-based management that focused on making patients as comfortable as possible. While this approach helped to improve quality of life, it does not target the key biochemical defect in MPS VI – arylsulfatase or ASB.2

Fortunately, clinicians now have an important tool in their possession – ERT with NAGLAZYME. First-line therapy with NAGLAZYME has provided for improvement in the outlook of MPS VI patients through endurance and lower GAG levels.1

Learn how enzyme replacement therapy with NAGLAZYME replaces ASB to reduce GAG accumulation.1

The value of early treatment

Early treatment may optimize the potential benefits of ERT with NAGLAZYME.7 In clinical trials, NAGLAZYME has been shown to improve walking and stair-climbing.1

Also in this section

Need more information?

In addition to visiting our practice resources section, you might want to review the 2007 Management Guidelines for Mucopolysaccharidosis VI.

 Next: Disease-focused therapy

REFERENCES

  1. NAGLAZYME [Prescribing Information]. Novato, CA: Biomarin; 2005.
  1. Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics. 2007;120:405-418.
  1. Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a Phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr. 2006;148:533-539.